SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i>V600E-mutant mCRC-Reference-Cited by-同舟云学术

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC

Published:2023-10-10 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Elez Elena¹,Kopetz Scott²,Tabernero Josep³,Bekaii-Saab Tanios⁴,Taieb Julien⁵,Yoshino Takayuki⁶,Manji Gulam⁷,Fernandez Kathrine⁸,Abbattista Antonello⁹,Zhang Xiaosong¹⁰,Morris Van K²

Affiliation:

1. Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain

2. University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Vall d'Hebron Hospital Campus & Vall d'Hebron Institute of Oncology, Universitat de Vic - Universitat Central de Catalunya, Barcelona, Spain

4. Mayo Clinic, Phoenix, AZ, USA

5. Georges Pompidou European Hospital, Université de Paris, Paris, France

6. National Cancer Center Hospital East, Kashiwa, Japan

7. Columbia University Irving Medical Center & NewYork-Presbyterian Hospital, New York, NY, USA

8. Pfizer Global Product Development-Oncology, Cambridge, MA, USA

9. Pfizer Global Product Development-Oncology, Milan, Italy

10. Pfizer, New York, NY, USA

Abstract

Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.

Funder

Funded by Pfizer

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-1249

Reference45 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. US FDA. US Food and Drug Administration Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer (2022). www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer#:∼:text=MSI%2DH%20and%20dMMR%20tumors,MSI%2DH%20or%20dMMR%20tumors

4. Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

5. Comprehensive molecular characterization of human colon and rectal cancer